Regeneron (REGN) Tops Q3 EPS by 14c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Pharma (REGN) PT Raised to $440 at SunTrust Robinson Humphrey
November 9, 2017 3:47 PM ESTSunTrust Robinson Humphrey analyst Suneja Yatin raised the price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $435.00) while maintaining a Hold rating following Q3 results highlighted by Eylea U.S. sales (+3.7% Q/Q), above (+2.1%) consensus.
The firm views near-term catalysts (Dupi in Asthma, anti-PD-1 in CSCC) as already priced-in.
... MoreRegeneron Pharma (REGN) PT Lowered to $465 at Jefferies
November 9, 2017 8:15 AM ESTJefferies lowered its price target on Regeneron Pharma (NASDAQ: REGN) to $465.00 (from $500.00) while maintaining a Hold rating.
... MoreShort-Dated Bullish Options Flow in Regeneron (REGN) Following 3Q Earnings Beat -Susquehanna
November 8, 2017 2:22 PM ESTSusquehanna options strategist Alison Edwards notes short-dated bullish options flow in Regeneron (NASDAQ: REGN), with shares of the company up 3% following the third quarter earnings beat, as investors purchased 800 each of this weeks Nov10 435 calls and next weeks Nov 435 calls.
... MoreRegeneron (REGN) and Sanofi (SNY) to Present New Analyses from Praluent Injection ODYSSEY Clinical Trial Program at AHA
November 7, 2017 8:26 AM ESTRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data analyses from the Praluent® (alirocumab) Injection ODYSSEY clinical trial program will be presented at the American Heart Association (AHA) Scientific Sessions 2017, November 11-15, in Anaheim, CA.
New analyses from the ODYSSEY ESCAPE trial evaluating treatment... More
